Erbitux data backs use as front-line therapy

Researchers announced that Erbitux proved effective as a front-line therapy against colon cancer, a big development for a therapy that is currently approved only after the unsuccessful use of chemotherapy. Data indicates that Erbitux delays progression of the disease when given as a combinational therapy with chemotherapy. That's good news for Bristol-Myers Squibb and ImClone, which share the revenue from the drug. Merck KGaA is ImClone's partner outside of the U.S. All three have been threatened by Amgen's Vectibix, which is putting pressure on the price of the drug.

- see the release on the data
- here's the report on Erbitux from CNN

Related Articles:
Analysts raise doubts on Erbitux ruling. Report
Erbitux effective in cancer trial. Report
Icahn takes control of ImClone as CEO departs. Report